The MarketWatch News Department was not involved in the creation of this content. Paraffin Market to Reach US$ 8,945.33 Million by 2032 at 4.13% CAGR, Shows New Maximize Market Research Analysis PUNE, ...

FRIENDSWOOD, Texas, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a ...

Karl: It was Jenny who came up with the idea to look at APIs, which tend to live a somewhat hidden life inside many modern applications. As we began researching API usage and breach statistics, we ...

Spotify is changing how its APIs work in Developer Mode, its layer that lets developers test their third-party applications using the audio platform’s APIs. The changes include a mandatory premium ...

Abstract: As REST APIs have become widespread in modern web services, comprehensive testing of these APIs is increasingly crucial. Because of the vast search space of operations, parameters, and ...

The special investigation team formed to delve into the death of Dueñas, Iloilo Vice Mayor Aimee Paz Lamasan has not received permission yet from her family on an autopsy requested on her remains.

The Italian startup will use the investment to build proprietary AI models, accelerate global expansion, and hire new talent. Italian cybersecurity startup Equixly on Tuesday announced raising €10 ...

Please provide your email address to receive an email when new articles are posted on . Experts have advised against routine testing for latent tuberculosis infection among people prescribed ...

Prescreening patients with psoriasis for tuberculosis (TB) before they start taking a biologic to treat their disease has been baked into the science of dermatologic practice, but a new position ...

NEW YORK – Breast cancer researchers at the Dana-Farber Cancer Institute and Harvard Cancer Center are investigating whether a CSF-1R inhibitor can overcome PARP inhibitor resistance associated with ...

Novo Nordisk is paying $240 million for global rights to a Phase 3-ready drug from Omeros that could rival immune disorder medications currently available from companies such as AstraZeneca, Novartis, ...